Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02041884
Other study ID # 2014/333-31
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2014
Est. completion date February 2017

Study information

Verified date January 2020
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to further evaluate the treatment for adults with ADHD used in our previous study (clinicaltrials.gov ID NCT01659164). It will now be converted to therapist supported, internet-delivered cognitive behavioral therapy (iCBT) with an additional smartphone application and evaluated through a randomized controlled trial during 12 weeks. The patients will be randomized to one of three conditions

- an active treatment group where the intervention is based on cognitive - and dialectical behavioral therapy (CBT and DBT) and the mobile app.

- an active ICBT-treatment based on psychoeducation, a CBT stress-reduction program and Applied Relaxation, and

- treatment as usual (TAU) / waiting list.

The main objective of the study is to evaluate if both of the treatment conditions will show better outcomes than TAU regarding decreased ADHD symptoms and increased functioning and life quality.

Another objective is to evaluate if the group receiving the active iCBT treatment (based on CBT and DBT) will show better outcomes in comparison to the control group regarding ADHD symptoms, overall functioning and life quality.


Description:

Approximately one-third of children with ADHD continue to be fully symptomatic into adulthood and many of the remainders often retain some residual problems that require treatment. Thus ADHD is a prevalent and chronic disabling disorder. Drugs provide first line treatment for adults with ADHD but are not enough for everybody, while we still lack proper evidence for promising psychological treatment. In addition to core symptoms of ADHD including regulatory difficulties of attention, activity level and impulses, difficulties with emotional regulation are common.

Follow-up studies of adults with ADHD have shown that only a few patients were offered sufficient treatment and support after the neuropsychiatric assessment and testing. The majority of adults diagnosed with ADHD are offered pharmacological treatment (stimulant medication) as the sole treatment. However, stimulant medication is not effective for up to 20-50 percent of adults as they may not experience symptom reduction or they are unable to tolerate the medication.

Consequently, the possible benefits of identifying and treating individuals with ADHD are extensive. Treatment of ADHD is preferably multimodal, i.e. consisting of more than one intervention.

Although literature regarding psychological treatment is relatively limited, studies of cognitive behavioral therapy (CBT) and dialectical behavior therapy (DBT) show that structured short-term therapies are promising in reducing ADHD related symptoms and increasing life quality. The main treatment focus is to enhance executive and organizational skills, improvement of consequence thinking and impulse control as well as emotion regulation skills. However, the range of trained psychologist in this field is rather limited. Using internet for delivering evidence-based psychological treatment can therefore be a innovative treatment alternative in order to make inaccessible treatment available to a large group of patients with ADHD.

The actual treatment project aims to evaluate if adults with ADHD can benefit from psychological treatment delivered through Internet. About 150-200 patients will be recruited through several outpatient clinics in Stockholm. They will be randomized to one of three conditions - active psychological treatment (based on CBT and DBT), an active alternative treatment where they undergo a psychoeducational support program (based on CBT) or to treatment as usual (TAU) / waiting list. The patients in the treatment conditions will have a personal contact via the internet with a psychologist within the 12 week treatment period. Assessments will be done before, during and after treatment, and after 3 and 12 months. The patients in the TAU condition will be offered iCBT treatment after they have filled out the post assessments (after 12 weeks and at 3rd month after treatment).


Recruitment information / eligibility

Status Completed
Enrollment 175
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Swedish citizen

- Clinical diagnosis of AD/HD according to DSM-IV or DSM-5

- Age 18-65

- 17 or more on the Adult ADHD Self Report Scale (ASRS v1.1)

- Not medically treated for adhd symptoms, or medically treated with central stimulants or comparable substance since at least one month with no significant changes in dosage and where no change in medical treatment is anticipated during the study time frame for the participant. No change in any other medical treatment is anticipated during the study time frame for the participant.

- Participant are by investigators considered able to follow through the training protocol and take part in measures taken during the study time frame

- The participant hasn´t used drugs the last 3 months

- Access to, and ability to use the Internet and mobile phone during the study time

- ability to understand Swedish in speech and writing

Exclusion Criteria:

- Diagnosed substance abuse according to DSM-IV or DSM-5 criteria within 3 months prior to screening. Earlier episodic substance abuse is not excluding

- Co-existing psychiatric condition that investigators believe will unable the participant to follow through the training protocol and take part in measures taken during the study time frame.

- IQ =85 according to a neuropsychological assessment

- Suicidality risk which is assessed during the first assessment interview.

- Organic brain syndrome

- Serious somatic condition which will unable the participant to participate (through the training protocol)or, is anticipated to have a negative impact on the treatment results

- Autism spectrum disorder where the function level is deemed too low for the treatment to be carried out which is defined as moderate or severe problems scale (level 2 and 3) according to DSM-5

- Severe depression defined by >34 p on MADRS-S or by a clinician´s assessment

- Other current psychological treatment for AD/HD or previous participation in such a treatment that is deemed to interfere with the study design

- severe writing and reading disabilities

- dyslexia of such degree that it impedes participation

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iCBT for Adults with ADHD
A skill training internet-based treatment program based on CBT and DBT interventions .
Internet stress-reduction
Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
Other:
Treatment as usual (TAU)/waiting list
Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)

Locations

Country Name City State
Sweden Internetpsykiatrienheten, Psykiatri Sydväst, SLSO Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Stockholm County Council, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment evaluation The investigators design own questions in order to evaluate how the participants have experienced the intervention regarding to knowledge, usage of the treatment methods and possible difficulties that they have experienced during treatment. during treatment and after 12 weeks of treatment (post)
Other CGI-I Clinical Global Impression - Improvement scale (rated by a clinician in order to detect level of improvement or worsening due to treatment) 12 weeks (post) and after 3 and 12 months (post)
Other TCS Treatment Credibility Scale (self report) Filled out by the patient at the 1st and 5th week of treatment
Other *CSQ-8 Client Satisfaction Questionnaire-8 (self report) - in order to evaluate the treatment satisfaction 12 weeks (post)
Primary Change (from baseline) in ASRS- v 1.1 ADHD Self Report Scale (ASRS) (self rating) Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in ADHD Rating Scale ADHD Rating Scale - assessed by an expert rater blind to Group allocation Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in EQ-5D Euroqol - (self report) to measure general health and quality of life Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in ISI Insomnia Severity Index - (self report) to measure insomnia symptoms Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in PSS-4 Perceived Stress Scale - (self report) to measure level of stress in everyday life Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in SDS Sheehan Disability Scale - (self report) to measure level of disability in everyday life Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in MADRS-S Montgomery-Åsberg Depression Rating Scale - (self report) to measure level of depression Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in DERS Difficulties of Emotion Regulation Scale - (self report) Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in AaQoL Adult ADHD Quality of Life Measure - self report Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in SWLS Satisfaction With Life Scale (self report) - measuring life quality. To evaluate the impact of the intervention on quality of Life, only the first three items in the scale will be used since the last two includes the whole Life-span and not just how Life quality is percived at the moment. Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Change (from baseline) in WAI-1 Work Ability Index (self report - one item) - a self estimation of working ability Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
Secondary Changes (from baseline) in CGI-S Clinical Global Impression - Severity scale - assessed by a blind expert rater - measuring symptom severity Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
See also
  Status Clinical Trial Phase
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Recruiting NCT06038942 - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress N/A
Not yet recruiting NCT06456372 - Digital Health Intervention for Children With ADHD N/A
Completed NCT05518435 - Managing Young People With ADHD in Primary Care Study
Active, not recruiting NCT04978792 - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD? N/A
Completed NCT03216512 - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD N/A
Completed NCT02829528 - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention N/A
Not yet recruiting NCT02906501 - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Completed NCT02562469 - ACTIVATE: A Computerized Training Program for Children With ADHD N/A
Terminated NCT02271880 - Improving Medication Adherence in ADHD Adolescents N/A
Recruiting NCT02255565 - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Phase 4
Completed NCT02463396 - Mindfulness Training in Adults With ADHD N/A
Completed NCT01673594 - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Phase 4
Terminated NCT01733680 - Amiloride Hydrochloride as an Effective Treatment for ADHD Early Phase 1
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Active, not recruiting NCT01137318 - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT01404273 - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00573859 - The Reinforcing Mechanisms of Smoking in Adult ADHD Phase 1/Phase 2
Completed NCT00586157 - Study of Medication Patch to Treat Children Ages 6-12 With ADHD Phase 4

External Links